Is Aristo Bio-Tech overvalued or undervalued?

As of 18 August 2025, the valuation grade for Aristo Bio-Tech has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently considered overvalued based on its key financial ratios, including a PE ratio of 18.44, an EV to EBITDA ratio of 10.26, and a PEG ratio of 4.50. These figures suggest that the stock price does not align well with its earnings growth potential, which raises concerns about its current valuation. When compared to peers, Aristo Bio-Tech's valuation stands out unfavorably. For instance, P I Industries has a much higher PE ratio of 35.35, while UPL, which is rated as attractive, has a PE of 34.63 and an EV to EBITDA of 8.52. This stark contrast highlights that Aristo Bio-Tech is not only overvalued relative to its peers but also lacks the growth metrics that would justify its current price. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -17.29%, contrasting sharply with the Sensex's positive return of 5.21%, further reinforcing the overvaluation narrative.